NCT05940259

68Ga-P3 PET/CT Imaging in Prostate

A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking University First Hospital · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.

Detailed description

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.\[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	[68Ga]P3	68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Timeline

• Start date: 2023-05-29
• Primary completion: 2025-07-31
• Completion: 2025-07-31
• First posted: 2023-07-11
• Last updated: 2024-11-07

Locations

1 site across 1 country: China